CAS:1005342-46-0LCL161

您的位置 : 首页 / Apoptosis / IAP / LCL161

LCL161 LCL161 Cat No. FB01124Cas No. 1005342-46-0

Synonyms: NVP-LCL161

LCL161 is an IAP inhibitor, inhibits XIAP activity in HEK293 cell with IC50 of 35 nM, also inhibits cIAP1 activity in MDA-MB-231 cell with IC50 of 0.4 nM.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.9975 mL
- 9.9874 mL
- 19.9748 mL
- 5 mM
- 0.3995 mL
- 1.9975 mL
- 3.9950 mL
- 10 mM
- 0.1997 mL
- 0.9987 mL
- 1.9975 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

1005342-46-0

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C26H33FN4O3S

运输

蓝冰

分子量

500.63

别名

NVP-LCL161

溶解度

DMSO	100.0 mg/mL (199.7 mM)
Water	Insoluble
Ethanol	20.0 mg/mL (39.9 mM) warming

动物实验配方

靶点数据

生物活性

描述LCL161 is an IAP family inhibitor which can bind and inhibit both XIAP and cIAP. Treatment with LCL161 could enhance the activity of different proapoptotic signaling pathways^[1]. LCL-161 at concentration of 2μM could induce cIAP degradation and activated downstream NFκB in Eμ-Myc cells^[2]. Treatment with LCL161 at concentration<10μM for 24h did not significantly affect protein level of XIAP protein level as Smac-mimetic treatment did not degrade XIAP, but can still inhibit the activity of XIAP measured by upregulation of cleaved caspases 9 and 3, in H929, MM1R and MM1S cells. LCL161 at concentration<15μM dose-dependently induced cell death of H929 and MM1S cells primarily driven by activation of the extrinsic apoptotic pathway^[3]. Combination of LCL161 (100mg/kg) with nilotinib showed synergistic effects and significantly delayed the onset of disease recurrence in a BCR-ABL-positive leukemia model^[1].
作用机制LCL-161 is a SMAC mimetic which can both disengage IAPs from caspases and induce proteasomal degradation of cIAP-1 and -2.^[2]
动物研究
剂量
Mice: 10 mg/kg^[3] (i.p.); 75 mg/kg^[4] (p.o.)

给药途径
i.p., p.o.

动物研究
剂量	Mice: 10 mg/kg^[3] (i.p.); 75 mg/kg^[4] (p.o.)
给药途径	i.p., p.o.